Five factors that will shape dealmaking over the coming 12 months

In the first half of 2022, Delaware courts issued several important decisions affecting M&A dealmaking

Buying an asset with operations in Russia remains permissible under sanctions laws, but any such process must be carefully considered

The SEC has followed through on promises to increase enforcement

New appointments in both the FTC and DOJ signal greater enforcement action on the horizon—with buyout firms a particular target

Under the Biden administration, CFIUS continues its rigorous assessment of security concerns across a wider range of sectors

Red-hot demand for warehouse space drove dealmaking in the sector in H1

Deal activity in consumer and retail decline as inflation worries hit confidence

Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking

Dealmaking in the US technology sector flourished in H1, despite a much-publicized fall in stock market valuations

A desire to consolidate and take advantage of relatively buoyant commodity prices is driving deals

Boosted by a few record-setting tech deals at the top end of the market, TMT continues to dominate US M&A value

After a series of rollercoaster years for the SPAC market, investors and sponsors are finding ways to improve deal integrity

Despite facing economic and regulatory hurdles in H1, PE dealmaking remains resilient, and looks set to reach its second-highest value on record

Deal value in the first half of 2022 could not match the record-breaking level of activity in 2021

Taking stock at this point in the year may make for slightly sobering reading for some, but the cyclical nature of the market means that, even as activity slows in one area, it can (and usually does) pick up in another—but what does this mean for leveraged finance markets in the months ahead?

Borrowers and lenders are seeking new opportunities in the face of growing market volatility